<DOC>
	<DOCNO>NCT02994407</DOCNO>
	<brief_summary>The trial conduct Asia , Europe North America . The aim study evaluate safety administration skin turoctocog alfa pegol ( SC N8-GP ) patient severe haemophilia A .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Study Turoctocog Alfa Pegol Injected Under Skin Patients With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male , age equal 18 year time signing informed consent , ( part A ) . Male , age equal 12 year time signing informed consent , ( part B ) . Diagnosis congenital haemophilia A base medical record ( FVIII activity &lt; 1 % ) . History 150 exposure day FVIII containing product . Previous participation trial . Participation define sign informed consent . ( Patients complete part A allow also participate part B . If , separate inform consent cover part B must sign . ) Immune compromise patient due human immunodeficiency virus ( HIV ) infection ( defined viral load great equal 400.000 copies/mL and/or cluster differentiation 4+ ( CD4+ ) lymphocyte count less equal 200/Î¼L perform screening define medical record old 6 month ) Any history FVIII inhibitor ( define medical record within 8 year randomisation ) Inhibitors FVIII ( great equal 0.6 Bethesda unit ( BU ) ) screening , measure Nijmegen modify Bethesda method central laboratory .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>